Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin
December 1, 2015Syndax Pharmaceuticals, a biopharmaceutical company focused on developing entinostat as a combination therapy in multiple cancer indications, continues to see clinical progress for entinostat in advanced breast cancer both in the U.S. and Japan.
More »
Epic Sciences' Chief Scientific Officer Named Leading Global Thinker by Foreign Policy Magazine
December 1, 2015Dena Marrinucci, Ph.D., is honored for developing the Epic Sciences liquid biopsy platform for detection and analysis of cancer.
More »
CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update
November 30, 2015Over 50% of the migraine patients needed to complete this Phase 3 trial have now been randomized. The objective of SAMURAI is to evaluate the efficacy of lasmiditan oral tablets in comparison to placebo for freedom from migraine headache pain.
More »